4 月 18 日,中国药物临床试验登记与信息公示平台显示,默沙东登记了一项比较 Sac-TMT(芦康沙妥珠单抗,TROP2 ADC)联合/不联合帕博利珠单抗与 TPC一线治疗不可切除/转移性三阴性乳腺癌(PD-L1 CPS<10)的 III 期研究(CTR20251453)。截图来自:药物临床试验登记与信息公示平台这是一项III 期、随机、开放标签研究(TroFuse-011),旨在既往未经系统...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.